Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced or metastatic non-small cell lung cancer with a HER2 mutation confirmed by a central lab
- You have not received any previous drug treatment for advanced lung cancer
- You have at least one measurable tumor outside the brain
- Your liver, kidneys, and heart are working well enough per study tests
- You do not have uncontrolled brain metastases, other active cancers, or certain heart, lung, or autoimmune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
This trial tests two drugs, SHR-A1811 and AK112, for people with advanced non-small cell lung cancer that has HER2 changes. It may help if you have not improved on standard treatment or if you have not yet had treatment.
Hear when a new Non-Small Cell Lung Cancer With HER2- Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.